Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGND) Receivables - Net (2016 - 2025)

Historic Receivables - Net for Ligand Pharmaceuticals (LGND) over the last 16 years, with Q3 2025 value amounting to $57.6 million.

  • Ligand Pharmaceuticals' Receivables - Net rose 6772.54% to $57.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $57.6 million, marking a year-over-year increase of 6772.54%. This contributed to the annual value of $38.4 million for FY2024, which is 1658.41% up from last year.
  • Latest data reveals that Ligand Pharmaceuticals reported Receivables - Net of $57.6 million as of Q3 2025, which was up 6772.54% from $41.3 million recorded in Q2 2025.
  • Over the past 5 years, Ligand Pharmaceuticals' Receivables - Net peaked at $85.5 million during Q4 2021, and registered a low of $28.0 million during Q2 2023.
  • Over the past 5 years, Ligand Pharmaceuticals' median Receivables - Net value was $38.5 million (recorded in 2025), while the average stood at $45.5 million.
  • As far as peak fluctuations go, Ligand Pharmaceuticals' Receivables - Net skyrocketed by 9550.86% in 2021, and later plummeted by 6439.68% in 2022.
  • Over the past 5 years, Ligand Pharmaceuticals' Receivables - Net (Quarter) stood at $85.5 million in 2021, then plummeted by 64.4% to $30.4 million in 2022, then rose by 8.19% to $32.9 million in 2023, then grew by 16.58% to $38.4 million in 2024, then skyrocketed by 49.99% to $57.6 million in 2025.
  • Its Receivables - Net was $57.6 million in Q3 2025, compared to $41.3 million in Q2 2025 and $38.5 million in Q1 2025.